Logo image of HOWL

WEREWOLF THERAPEUTICS INC (HOWL) Stock Fundamental Analysis

NASDAQ:HOWL - Nasdaq - US95075A1079 - Common Stock - Currency: USD

1.21  -0.09 (-6.92%)

After market: 1.21 0 (0%)

Fundamental Rating

2

HOWL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. HOWL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HOWL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year HOWL has reported negative net income.
In the past year HOWL has reported a negative cash flow from operations.
In the past 5 years HOWL always reported negative net income.
HOWL had a negative operating cash flow in each of the past 5 years.
HOWL Yearly Net Income VS EBIT VS OCF VS FCFHOWL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

The Return On Assets of HOWL (-67.52%) is worse than 63.20% of its industry peers.
HOWL has a Return On Equity (-126.36%) which is in line with its industry peers.
Industry RankSector Rank
ROA -67.52%
ROE -126.36%
ROIC N/A
ROA(3y)-36.84%
ROA(5y)-50.48%
ROE(3y)-57.88%
ROE(5y)-67.48%
ROIC(3y)N/A
ROIC(5y)N/A
HOWL Yearly ROA, ROE, ROICHOWL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

HOWL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HOWL Yearly Profit, Operating, Gross MarginsHOWL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

4

2. Health

2.1 Basic Checks

HOWL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HOWL has more shares outstanding
Compared to 5 years ago, HOWL has more shares outstanding
Compared to 1 year ago, HOWL has an improved debt to assets ratio.
HOWL Yearly Shares OutstandingHOWL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
HOWL Yearly Total Debt VS Total AssetsHOWL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

HOWL has an Altman-Z score of -6.30. This is a bad value and indicates that HOWL is not financially healthy and even has some risk of bankruptcy.
HOWL has a Altman-Z score of -6.30. This is in the lower half of the industry: HOWL underperforms 65.35% of its industry peers.
A Debt/Equity ratio of 0.46 indicates that HOWL is not too dependend on debt financing.
The Debt to Equity ratio of HOWL (0.46) is worse than 73.79% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF N/A
Altman-Z -6.3
ROIC/WACCN/A
WACC8.79%
HOWL Yearly LT Debt VS Equity VS FCFHOWL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 8.09 indicates that HOWL has no problem at all paying its short term obligations.
HOWL has a better Current ratio (8.09) than 70.74% of its industry peers.
HOWL has a Quick Ratio of 8.09. This indicates that HOWL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 8.09, HOWL is in the better half of the industry, outperforming 70.92% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.09
Quick Ratio 8.09
HOWL Yearly Current Assets VS Current LiabilitesHOWL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for HOWL have decreased strongly by -50.46% in the last year.
HOWL shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -92.95%.
EPS 1Y (TTM)-50.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.56%
Revenue 1Y (TTM)-92.95%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 5.47% on average over the next years.
HOWL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 98.95% yearly.
EPS Next Y-12.74%
EPS Next 2Y-1.97%
EPS Next 3Y-1.58%
EPS Next 5Y5.47%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y98.95%

3.3 Evolution

HOWL Yearly Revenue VS EstimatesHOWL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
HOWL Yearly EPS VS EstimatesHOWL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HOWL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HOWL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HOWL Price Earnings VS Forward Price EarningsHOWL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HOWL Per share dataHOWL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.97%
EPS Next 3Y-1.58%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HOWL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

WEREWOLF THERAPEUTICS INC

NASDAQ:HOWL (6/17/2025, 8:00:01 PM)

After market: 1.21 0 (0%)

1.21

-0.09 (-6.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)N/A N/A
Inst Owners62.81%
Inst Owner Change-2.3%
Ins Owners1.51%
Ins Owner Change0%
Market Cap54.29M
Analysts88.33
Price Target8.57 (608.26%)
Short Float %4.92%
Short Ratio4.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.67%
Min EPS beat(2)-7.8%
Max EPS beat(2)0.47%
EPS beat(4)2
Avg EPS beat(4)-0.51%
Min EPS beat(4)-7.8%
Max EPS beat(4)9.61%
EPS beat(8)5
Avg EPS beat(8)15.52%
EPS beat(12)8
Avg EPS beat(12)16.74%
EPS beat(16)9
Avg EPS beat(16)-46.52%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)-66.73%
Min Revenue beat(4)-100%
Max Revenue beat(4)33.09%
Revenue beat(8)3
Avg Revenue beat(8)16.69%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-17.65%
PT rev (3m)-21.25%
EPS NQ rev (1m)1.71%
EPS NQ rev (3m)9.09%
EPS NY rev (1m)0%
EPS NY rev (3m)3.22%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 47.5
P/FCF N/A
P/OCF N/A
P/B 0.95
P/tB 0.95
EV/EBITDA N/A
EPS(TTM)-1.64
EYN/A
EPS(NY)-1.69
Fwd EYN/A
FCF(TTM)-1.34
FCFYN/A
OCF(TTM)-1.33
OCFYN/A
SpS0.03
BVpS1.28
TBVpS1.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -67.52%
ROE -126.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.84%
ROA(5y)-50.48%
ROE(3y)-57.88%
ROE(5y)-67.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.05%
Cap/Sales 12.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.09
Quick Ratio 8.09
Altman-Z -6.3
F-Score2
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)128.59%
Cap/Depr(5y)197.28%
Cap/Sales(3y)13.11%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.56%
EPS Next Y-12.74%
EPS Next 2Y-1.97%
EPS Next 3Y-1.58%
EPS Next 5Y5.47%
Revenue 1Y (TTM)-92.95%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y98.95%
EBIT growth 1Y-63.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.54%
EBIT Next 3Y-9.75%
EBIT Next 5Y0.98%
FCF growth 1Y-48.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-63.72%
OCF growth 3YN/A
OCF growth 5YN/A